Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SVRA Stock Forecast 2026-2027
$5.81
Current Price
$1.17B
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SVRA Price Targets
+175.4%
To High Target of $16.00
+76.4%
To Median Target of $10.25
+54.9%
To Low Target of $9.00
SVRA Price Momentum
-3.6%
1 Week Change
+8.0%
1 Month Change
+148.3%
1 Year Change
-3.6%
Year-to-Date Change
-17.1%
From 52W High of $7.01
+158.2%
From 52W Low of $2.25
📊 TOP ANALYST CALLS
Did SVRA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Savara is one of their latest high-conviction picks.
Latest SVRA Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, SVRA has a bullish consensus with a median price target of $10.25 (ranging from $9.00 to $16.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $5.81, the median forecast implies a 76.4% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Benjamin Burnett at Wells Fargo, suggesting a 54.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SVRA Analyst Ratings
8
Buy
0
Hold
0
Sell
SVRA Price Target Range
Low
$9.00
Average
$10.25
High
$16.00
Current: $5.81
Latest SVRA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SVRA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 23, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $10.00 |
| Dec 18, 2025 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $9.00 |
| Nov 14, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Nov 13, 2025 | Citizens | Market Outperform | Maintains | $N/A | |
| Oct 23, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Sep 9, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Sep 8, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Sep 3, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 15, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Aug 15, 2025 | HC Wainwright & Co. | Buy | Upgrade | $N/A | |
| Jun 1, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| May 29, 2025 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| May 28, 2025 | Evercore ISI Group | In-Line | Maintains | $N/A | |
| May 28, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| May 28, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Mar 31, 2025 | Evercore ISI Group | Hold | Maintains | $N/A | |
| Mar 28, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 20, 2024 | Wells Fargo | Overweight | Initiates | $N/A | |
| Dec 19, 2024 | JMP Securities | Market Outperform | Reiterates | $N/A | |
| Nov 13, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A |
Savara Inc. (SVRA) Competitors
The following stocks are similar to Savara based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Savara Inc. (SVRA) Financial Data
Savara Inc. has a market capitalization of $1.17B with a P/E ratio of -10.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -80.0%.
Valuation Metrics
Market Cap
$1.17B
Enterprise Value
$1.28B
P/E Ratio
-10.9x
PEG Ratio
-0.4x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+13.9%
Current Ratio
13.5x
Debt/Equity
17.1x
ROE
-80.0%
ROA
-40.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Savara Inc. (SVRA) Business Model
About Savara Inc.
What They Do
Develops therapies for rare respiratory diseases.
Business Model
Savara Inc. focuses on creating and commercializing inhalation therapies specifically designed for rare and chronic respiratory diseases. The company generates revenue through the development of innovative treatment options that cater to patients with limited choices, targeting conditions such as pulmonary alveolar proteinosis and cystic fibrosis.
Additional Information
Savara Inc. is dedicated to addressing unmet medical needs in the healthcare sector, emphasizing patient safety and efficacy in its products. Its position in the niche market of rare diseases allows it to contribute significantly to advancements in respiratory healthcare, marking its importance in both the medical and pharmaceutical industries.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
70
CEO
Mr. Matthew Pauls J.D., M.B.A.
Country
United States
IPO Year
2017
Website
www.savarapharma.comSavara Inc. (SVRA) Latest News & Analysis
Latest News
Quick Summary
On June 22, 2026, 394,528 shares of Common Stock were sold for approximately $2.24 million at an average price of $5.68 per share, representing 42.40% of the executive's holdings.
Why It Matters
A significant insider sale of 42.40% of an executive's stock holdings may signal potential lack of confidence in the company's future, impacting investor sentiment and share price.
Source: The Motley Fool
Market Sentiment:
Negative
Savara Announces New Employment Inducement Grant
1 month ago
Quick Summary
Savara Inc. granted inducement awards to four new employees, including options for 36,500 shares and restricted stock units, as part of its compensation strategy.
Why It Matters
Savara's grant of stock options and RSUs to new employees signals growth and recruitment, which may enhance productivity and innovation, potentially boosting future stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Savara Inc. (Nasdaq: SVRA) announced that CFO Dave Lowrance will step down for health reasons on July 15, 2026, and will separate financial and administrative responsibilities.
Why It Matters
Leadership changes can impact company stability and strategic direction. A CFO departure may lead to concerns about financial management and future performance, affecting investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Savara Inc. will host one-on-one meetings and a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, at 11:05 AM ET. A live webcast will be available afterward.
Why It Matters
Savara Inc.'s participation in the Jefferies Global Healthcare Conference highlights its visibility and potential for investment interest, signaling engagement with key stakeholders in the healthcare sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Savara is evolving into a rare disease commercial entity with MOLBREEVI for autoimmune PAP. It has $203M in liquidity and potential for $150M non-dilutive capital. PDUFA date is November 22, 2026.
Why It Matters
Savara's shift to a rare disease focus and strong cash position enhance growth potential. Positive regulatory milestones and Phase 3 data could lead to significant value creation.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Savara Inc. will present new exercise capacity data from its Phase 3 IMPALA-2 trial for molgramostim, targeting aPAP, at the ATS 2026 Conference in May 2026.
Why It Matters
Savara's presentation on new clinical trial data could influence investor sentiment by signaling progress in drug development, potentially impacting stock performance and market valuation.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About SVRA Stock
What is Savara Inc.'s (SVRA) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Savara Inc. (SVRA) has a median price target of $10.25. The highest price target is $16.00 and the lowest is $9.00.
Is SVRA stock a good investment in 2027?
According to current analyst ratings, SVRA has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.81. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SVRA stock?
Wall Street analysts predict SVRA stock could reach $10.25 in the next 12 months. This represents a 76.4% increase from the current price of $5.81. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Savara Inc.'s business model?
Savara Inc. focuses on creating and commercializing inhalation therapies specifically designed for rare and chronic respiratory diseases. The company generates revenue through the development of innovative treatment options that cater to patients with limited choices, targeting conditions such as pulmonary alveolar proteinosis and cystic fibrosis.
What is the highest forecasted price for SVRA Savara Inc.?
The highest price target for SVRA is $16.00 from at , which represents a 175.4% increase from the current price of $5.81.
What is the lowest forecasted price for SVRA Savara Inc.?
The lowest price target for SVRA is $9.00 from Benjamin Burnett at Wells Fargo, which represents a 54.9% increase from the current price of $5.81.
What is the overall SVRA consensus from analysts for Savara Inc.?
The overall analyst consensus for SVRA is bullish. Out of 3 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.25.
How accurate are SVRA stock price projections?
Stock price projections, including those for Savara Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 3:37 PM UTC